Johnson and Johnson warn that pharmaceutical tariffs can cause drug deficiency

Be aware of free updates

Just subscribe to The pharmaceutical sector Myft Digest – delivered directly to the mailbox.

Chief Executive Director Johnson and Johnson warned that the potential tariffs in the US in the pharmaceutical industry could lead to lack of medicines.

The industry was excluded from the wide tariffs announced this month, but the Trump administration made it clear that it was considering using them to try to increase domestic production.

Currently, the United States has no tariffs for pharmaceuticals from being released from the 1994 World Trade Organization Trade Organization.

Hooquin Duato, who heads one of the world’s largest pharmaceutical and medical companies, said in a call with analysts on Tuesday: “There is a reason why pharmaceutical tariffs are zero. This is because tariffs can create disturbances in the supply chain.”

Medical devices and technologies, as well as surgical robots made by J&B, were affected by new tariffs in the US.

“If you want to create production facilities in the US, both in Med Tech and in pharmaceuticals, the most effective response is not tariffs but tax policy,” Dua said.

In March, J&B announced that the $ 55 billion in the new four -year -old factories, which, he said, increased by 25 percent of investments compared to previous four years.

On Monday, US Administration said This began an investigation into the consequences of national security, based on the import of medicines. The probe was started on April 1 and will be consulted on 21 days.

The Duat said he believed that it is important for the healthcare campaign to work with the administration to “mitigate some vulnerabilities that exist … in our healthcare supply network”, in response to the question of investigation and potential tariffs.

Chief Financial Director J & J Joe Walk said the company wants to “be sending the administration and their process”.

The pharmaceutical industry usually refrained from the public condemnation of the tariffs, hoping that behind -the -scenes talks would prevail. But the Dua comments come after Michel Demora, the chairman of Astrazeneca, warned on Friday that tariffs could harm patients, health care systems and “restrict justice in the field of health”.

In the results published on Tuesday, J&B supported its adjusted divorced prognosis for a share per year at $ 10.50-10.70, despite the fact that given $ 400 million costs related mainly to medical tariffs.

Its sales in the first quarter of the year amounted to $ 21.9 billion, which is 2.4 percent compared to the same period last year. Analysts expected $ 21.6 billion.